Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease

被引：10

作者：

Chuang, Wan-Long ^{[1
]}

Hu, Tsung-Hui ^{[2
]}

Buggisch, Peter ^{[3
]}

Moreno, Christophe ^{[4
]}

Su, Wei-Wen ^{[5
]}

Biancone, Luigi ^{[6
]}

Camargo, Marianne ^{[7
]}

Hyland, Robert ^{[7
]}

Lu, Sophia ^{[7
]}

Kirby, Brian J. ^{[7
]}

Dvory-Sobol, Hadas ^{[7
]}

Osinusi, Anu ^{[7
]}

Gaggar, Anuj ^{[7
]}

Peng, Cheng-Yuan ^{[8
]}

Liu, Chen-Hua ^{[9
]}

Sise, Meghan E. ^{[10
]}

Mangia, Alessandra ^{[11
]}

机构：

[1] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan

[2] Kaohsiung Chang Gung Mem Hosp, Kaohsiung, Taiwan

[3] Liver Ctr Hamburg, Ifi Inst Interdisziplinare Med, Hamburg, Germany

[4] Univ Libre Bruxelles, CUB Hop Erasme, Brussels, Belgium

[5] Changhua Christian Hosp, Changhua, Taiwan

[6] Univ Torino, Turin, Italy

[7] Gilead Sci, Foster City, CA USA

[8] China Med Univ Hosp, Taichung, Taiwan

[9] Natl Taiwan Univ Hosp, Taipei, Taiwan

[10] Massachusetts Gen Hosp, Boston, MA 02114 USA

[11] Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2021年 / 116卷 / 09期

关键词：

SOFOSBUVIR; LEDIPASVIR; HCV;

D O I：

10.14309/ajg.0000000000001281

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

INTRODUCTION: We evaluated 8, 12, or 24 weeks of ledipasvir/sofosbuvir in patients with hepatitis C virus and end-stage renal disease undergoing dialysis. METHODS: Primary efficacy end point was sustained virologic response 12 weeks after treatment. Primary safety end point was treatment discontinuation because of adverse events (AEs). RESULTS: Ninety-four percent (89/95) achieved sustained virologic response 12 weeks after treatment. Six patients died during treatment (n = 4) or before study completion (n = 2); no deaths were related to treatment. No patients discontinued treatment because of AEs. Thirteen percent had serious AEs; none were related to treatment. DISCUSSION: Treatment with ledipasvir/sofosbuvir was safe and effective in patients with end-stage renal disease undergoing dialysis.

引用

页码：1924 / 1928

页数：5

共 15 条

[1] AbbVie Inc, 2018, MAVYRET GLEC PIBR TA
[2] AbbVie Inc, 2016, VIEKIRA XR DAS OMB P
[3] Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Afdhal, Nezam
Zeuzem, Stefan
Kwo, Paul
Chojkier, Mario
Gitlin, Norman
Puoti, Massimo
Romero-Gomez, Manuel
Zarski, Jean-Pierre
Agarwal, Kosh
Buggisch, Peter
Foster, Graham R.
Braeu, Norbert
Buti, Maria
Jacobson, Ira M.
Subramanian, G. Mani
Ding, Xiao
Mo, Hongmei
Yang, Jenny C.
Pang, Phillip S.
Symonds, William T.
McHutchison, John G.
Muir, Andrew J.
Mangia, Alessandra
Marcellin, Patrick
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (20) : 1889 - 1898
[4] Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Afdhal, Nezam
Reddy, K. Rajender
Nelson, David R.
Lawitz, Eric
Gordon, Stuart C.
Schiff, Eugene
Nahass, Ronald
Ghalib, Reem
Gitlin, Norman
Herring, Robert
Lalezari, Jacob
Younes, Ziad H.
Pockros, Paul J.
Di Bisceglie, Adrian M.
Arora, Sanjeev
Subramanian, G. Mani
Zhu, Yanni
Dvory-Sobol, Hadas
Yang, Jenny C.
Pang, Phillip S.
Symonds, William T.
McHutchison, John G.
Muir, Andrew J.
Sulkowski, Mark
Kwo, Paul
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (16) : 1483 - 1493
[5] DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting
Beinhardt, Sandra
Al Zoairy, Ramona
Ferenci, Peter
Kozbial, Karin
Freissmuth, Clarissa
Stern, Rafael
St Attermayer, Albert Friedrich
Stauber, Rudolf
Strasser, Michael
Zoller, Heinz
Watschinger, Bruno
Schmidt, Alice
Trauner, Michael
Hofer, Harald
Maieron, Andreas
[J]. TRANSPLANT INTERNATIONAL, 2016, 29 (09) : 999 - 1007
[6] Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis
Borgia, Sergio M.
Dearden, Janet
Yoshida, Eric M.
Shafran, Stephen D.
Brown, Ashley
Ben-Ari, Ziv
Cramp, Matthew E.
Cooper, Curtis
Foxton, Matthew
Fernandez Rodriguez, Conrado
Esteban, Rafael
Hyland, Robert
Lu, Sophia
Kirby, Brian J.
Meng, Amy
Markova, Svetlana
Dvory-Sobol, Hadas
Osinusi, Anu O.
Bruck, Rafael
Ampuero, Javier
Ryder, Stephen D.
Agarwal, Kosh
Fox, Raymond
Shaw, David
Haider, Shariq
Willems, Bernard
Lurie, Yoav
Calleja, Jose Luis
Gane, Edward J.
[J]. JOURNAL OF HEPATOLOGY, 2019, 71 (04) : 660 - 665
[7] THE EFFECT OF RENAL IMPAIRMENT AND END STAGE RENAL DISEASE ON THE SINGLE-DOSE PHARMACOKINETICS OF PSI-7977
Cornpropst, M. T.
Denning, J. M.
Clemons, D.
Marbury, T. C.
Alcorn, H.
Smith, W. B.
Sale, M.
Fang, L.
Berrey, M. M.
Symonds, W. T.
[J]. JOURNAL OF HEPATOLOGY, 2012, 56 : S433 - S433
[8] Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure
Dumortier, Jerome
Bailly, Francois
Pageaux, Georges-Philippe
Vallet-Pichard, Anais
Radenne, Sylvie
Habersetzer, Francois
Gagnieu, Marie-Claude
Grange, Jean-Didier
Minello, Anne
Guillaud, Olivier
Kamar, Nassim
Alric, Laurent
Leroy, Vincent
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 (12) : 2065 - 2071
[9] The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies
Fabrizi, F.
Takkouche, B.
Lunghi, G.
Dixit, V.
Messa, P.
Martin, P.
[J]. JOURNAL OF VIRAL HEPATITIS, 2007, 14 (10) : 697 - 703
[10] Treatment Choices for Hepatitis C in Patients with Kidney Disease
Fabrizi, Fabrizio
Messa, Piergiorgio
[J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 13 (05): : 793 - 795

← 1 2 →